first case is it would be anticipated or it would have been obvious what i am and claim construction actually comes into the not infringement argument as well your honor because the corner error when she failed to recognize that the intrenchments question so what not again if we go to the concept of the construction of the claim which the court always has to look at the only factual disputes became when submit that once this court came out with that in that ruling and phillips and i talked about the public notice and it said when you look at the claims you don't look at them in a vacuum you have to look at what the purpose of the baton is in this case on she found that we put in a terror quoting directly on that a member's all or and there was no dispute about that she should have found there was not infringement and if this court are you saying that's  because that close to her interpretation of the claims who once she made her factual finding that we put that until quoting directly on the map result and you read these patterns independent and each one of which compels either vacation or reversal of the court the first is the fact that at the time the court entered its opinion it lacked subject matter jurisdiction to decide the matter as to and actually laboratories because there was no lingering claim  those have to be accepted by the of da if they reject the reports don't need pediatric take but that's true your honor they have to accept in the first instance but there's ongoing reporting requirements on behalf of all briefs the number of ways that the references relied on apple tax did not meet the limitations of any of the claims of the five zero five or two three  tried to apply these references to the thirty two thirty patent but for a number of reasons including if the fact that it did not lead the acid label pharmaceutically active ingredient limitation this very same argument your argument that their process to prepare their product doesn't involve a separate coding that the court correctly in our view decided does not matter how that product is prepared now apple techs would have you believe that there was some disclaimer or something in the patent that they disclaimed he also mentioned this concept that they in that the app a text product is different than anything that's the slows down the five four nine five pad different materials in the core different processing conditions different in terra coating materials and it produces a different product similarly when you look at the the patent there is no example in the patent that is said to be a prior art product which is similar to what happened to x does appetite's designed it to make a specific formulation and there is a wealth of proof in the record that that formulation when fully formed at the end of its manufacturing process includes the claimed subcode a wealth of information on that astra zeneca submitted tests using a number of different analytical methods to demonstrate that the sub coding in the apa text product met all the limitations of the claimed it was continuous it was inert it was disposed between the core and the in terre haute ing in the final formulation as the claims require now of course the text doesn't like the way the court way that evidence but it's not a claim construction construction issue there it is and the court clearly didn't there's an issue there the issue they pressed this morning is a claim construction issue as i understand it you just think that they are they're wrong i think there are something to the claim that stretching absolutely i think i think they're wrong and i  i like to talk a little bit about jurisdiction term of before you get to that point can i ask you a question about public huge legal issues reduced to actually the invention was not reduced to practice and there's no finding that it was reduced to practice in one nine hundred eighty three but there are in fact a finding to the opposite to the contrary absolutely the court found that it was not reduced  practice it wasn't ready for patenting because this additional experimentation had not been completed and had not been done and why was that not produced to practice was it because stability had not been proved absolutely the patent question deals with two very important and troubling problems with the members of america's all of the highly unstable material it's unstable an  of action you had a formulation that had gastric acid resistance what we call stable in the body so you had this ability on the shelf problem and then you also had the stable in the body that was  coatings help towards solving that problem but if that was one of the surprising things about this method is all formulation but the entire record alone didn't allow the astra zeneca to prepare might be a viable option but until they had the testing till they had this ability testing the armchair on the shelf test it and the clinical testing with people with these higher amounts of acid in their in their in their gastric system to show that it actually work it didn't really know whether this works for its intended purpose and you can't lose sight of the fact that some of the claim in these pa right but you're saying the findings here were different writing here were different than the court clearly found that this invention was not ready for pat before the critical day could you tell us a little bit about the conditions imposed on the participants in the open label clinical testing what condition of confidentiality if any were the all of the clinicians of course signed the protocol protocol which had conditions of confidentiality in those protocols the individuals in the clinical and the patients were given these samples and they didn't know what they were they didn't know what was in the bottle they didn't know it was a formulation they didn't know anything at no idea and wouldn't have known that this forth would be a non public use it's our position that any clinical trial of an experimental medicine well this is absurd from an experiment participant am trying to tease apart experimental use from public use it is it your argument then that for whatever reason suppose that this is being done purely for the purpose of satisfying an f d a require and let's assume that you've already got your drug is that a public use you think well i think a lot depends on the details of the use and what would be the most important detail that would make something nonpublic a non public use in a clinical trial setting that the clinical clinicians are following the protocol that is directed and controlled by the the company developing the product that there are controls over the wide use of this material by the patien of controls that were in place in the tests that impacts contents were of work work work public you know these this is these are the way these are the way that clinical trials have to be done so you know clearly there are circumstances where medicines need to be tested to assess whether they are safe effective they have practice or whether this kind of test is just not a public use at all in which case that that clock does not start running well i don't think there needs to be that bright line rule the laws are already in place that there  a body of page law on what it means to be a public use and there's a body of case law on what it means to be an experimental use i think those concepts can just as clearly be applied to the clinical test scenario as they can be to any other set of circumstances what the case the say you've got to look at the totality of the circumstances in these public use evaluations to see what it what is that what is the invention claim what are the realities of experimentation in this art what are the realities was there commercial exploitation was there some act or action that is in it and at brief but i would i would ask that this court especially on this issue the carefully at what is cited in support of these some of these broad statements that are in the brief testimony on that issue was that there was some indication that the stability problem had been addressed by using this three layer formulation you can do it celebrated stability test and you c zeneca also said is that you didn't know and you couldn't know whether it worked as a pharmaceutical formulation until it is testing people until people took the sample and you therefore irrelevant the public use initial tests that evidence that the phase two formulation had this gastric acid resistance probably that in the body it was not that gastric acid resistance was not as  good as necessary for a viable product that's what caused the inventors to have to sort of core back to the drawing board to solve the solve that problem that with a face to face to for saw the on the shelf stability problem it at the out when reacting compound to the core which intended which are enhance the stable stability of the map is all but it didn't solve the two problems the other problem which was the gas or passive resistance to get through the stomach to successfully get to the stomach without wheat you were about to i think a little earlier to turn to the jurisdictional question could you address that  we we do believe that the court had jurisdiction to hear this case under to said we want a four a and big and but you don't even have to address that issue because the court had also had jurisdiction to continue to hear this case because ashley has made claims for willful infringement under section two eighty five of the patents that use so that trial the court maintain jurisdiction to decide the case based on the pendency of a claim or wouldn't that argument apply would mean that there'd be no such thing as a mood equitable claim since for example there's always an issue costs for example the the court might decide that the prevailing party should should be given an award of costs that would that be enough to an expiration so that you doesn't say that you know only until the patent expires it says not earlier taylor and i don't think we'll give you an prior court's decision this court's decision in the first wave took place before the on bond decision adults and the on bank decision authority tells us all of them only the interpretation to be given a term can only be determined in confirmed with the full understanding of what the inventors actually invented and intended to envelop with the claim the construction that stage true to the claim language of most naturally aligns of the atoms destruction of the invention would be in the end the correct  or under a proper claim construction at that point there could be no one for enjoyment because there is no sub coating as this patent defines this patent defines that sub coating as preventing the coating from coming in contact with the members all or well the evidence at trial and this court's finding the trial court's finding was that's exactly what happened textiles goes on to say our members will rapidly decomposes by director by finding that these clinical trials were gauged to determine the stability of the formulation which is what these patents directed to those were instead to see for example this particular phase three clinical trial was this formulation already proved effective disease was it effective for new indications what is that in your view makes this clinical trial a public use what put another way what would i have to do in order to avoid triggering the public use in in doing this for the amusement of everyone involved mostly just pushes is it a public use if it's done on a i'm sure chambers are in fact private and i would suggest that if it isn't back contained total control i'm tamed and it's not for purposes of gaining commercial advantage and that's not a public use but even here the district court found there was public disclosure and in fact in her